Wutah pendapatan taun lumaku: Reata Pharma (RETA)

Logo grafis Reata Pharma (RETA)

Reata Pharmaceuticals operates a business that is independent of economic cycles due to the inelastic demand for the treatment of rare pathologies. The 12-month year-over-year sales trend illustrates the expansion of Skyclarys in Europe and the resulting revenue growth. The value of reflects the most recent metric value. Market confidence is bolstered by the company's integration into the structure of a global leader and management's focus on scaling the product.

Reata Pharmaceuticals (RETA): Wutah pendapatan YoY sajrone 12 wulan kepungkur saka 04.07.2022 nganti 18.11.2026

Reata Pharma (RETA) - rincian metrik lan laporan keuangan

- rega saham lan target rega konsensus:
- indikator kapitalisasi bursa perusahaan:
Ringkesan analitik perusahaan:RETA (Reata Pharmaceuticals)
Produk merek Reata

Reata Pharmaceuticals (RETA) remains insulated from macroeconomic shocks due to its unique medical developments, making the year-over-year (LTM) gross revenue trend a key indicator of this defensive asset's resilience. This metric measures the relative change in trailing twelve-month rolling revenue, allowing investors to identify hidden cash flow deceleration between quarterly reports to minimize the risk of a deep capital drawdown.